CRNO B Stock Overview
Cereno Scientific AB (publ), clinical stage biotech company, develops therapeutics to treat cardiovascular and rare diseases through epigenetic modulation worldwide.
+ 1 more risk
Cereno Scientific Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||kr2.85|
|52 Week High||kr5.70|
|52 Week Low||kr2.00|
|1 Month Change||2.15%|
|3 Month Change||-16.18%|
|1 Year Change||-40.69%|
|3 Year Change||-22.97%|
|5 Year Change||-63.46%|
|Change since IPO||-54.40%|
Recent News & Updates
|CRNO B||SE Biotechs||SE Market|
Return vs Industry: CRNO B underperformed the Swedish Biotechs industry which returned -31.3% over the past year.
Return vs Market: CRNO B underperformed the Swedish Market which returned -27.6% over the past year.
|CRNO B volatility|
|CRNO B Average Weekly Movement||7.2%|
|Biotechs Industry Average Movement||8.1%|
|Market Average Movement||6.9%|
|10% most volatile stocks in SE Market||11.6%|
|10% least volatile stocks in SE Market||4.3%|
Stable Share Price: CRNO B is not significantly more volatile than the rest of Swedish stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: CRNO B's weekly volatility (7%) has been stable over the past year.
About the Company
Cereno Scientific AB (publ), clinical stage biotech company, develops therapeutics to treat cardiovascular and rare diseases through epigenetic modulation worldwide. Its lead drug candidate is CS1, a product candidate that is in Phase II clinical trial for the treatment of rare disease pulmonary arterial hypertension and thrombotic indications. It is also involved in developing histone deacetylase inhibitor that is in the preclinical stage for the treatment of cardiovascular diseases.
Cereno Scientific Fundamentals Summary
|CRNO B fundamental statistics|
Is CRNO B overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|CRNO B income statement (TTM)|
|Cost of Revenue||kr0|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
Nov 16, 2022
|Earnings per share (EPS)||-0.18|
|Net Profit Margin||-38.18%|
How did CRNO B perform over the long term?See historical performance and comparison
Is CRNO B undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 3/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for CRNO B?
Other financial metrics that can be useful for relative valuation.
|What is CRNO B's n/a Ratio?|
Price to Sales Ratio vs Peers
How does CRNO B's PS Ratio compare to its peers?
|CRNO B PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
HAMLET B Hamlet Pharma
CRNO B Cereno Scientific
Price-To-Sales vs Peers: CRNO B is good value based on its Price-To-Sales Ratio (5.9x) compared to the peer average (19.3x).
Price to Earnings Ratio vs Industry
How does CRNO B's PE Ratio compare vs other companies in the SE Biotechs Industry?
Price-To-Sales vs Industry: CRNO B is good value based on its Price-To-Sales Ratio (5.9x) compared to the Swedish Biotechs industry average (19x)
Price to Sales Ratio vs Fair Ratio
What is CRNO B's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||5.9x|
|Fair PS Ratio||13.5x|
Price-To-Sales vs Fair Ratio: CRNO B is good value based on its Price-To-Sales Ratio (5.9x) compared to the estimated Fair Price-To-Sales Ratio (13.5x).
Share Price vs Fair Value
What is the Fair Price of CRNO B when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate CRNO B's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate CRNO B's fair value for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
How is Cereno Scientific forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CRNO B is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: CRNO B is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: CRNO B is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: CRNO B is forecast to have no revenue next year.
High Growth Revenue: CRNO B is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: CRNO B is forecast to be unprofitable in 3 years.
Discover growth companies
How has Cereno Scientific performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CRNO B is currently unprofitable.
Growing Profit Margin: CRNO B is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: CRNO B is unprofitable, and losses have increased over the past 5 years at a rate of 23.5% per year.
Accelerating Growth: Unable to compare CRNO B's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CRNO B is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-16.7%).
Return on Equity
High ROE: CRNO B has a negative Return on Equity (-12.25%), as it is currently unprofitable.
Discover strong past performing companies
How is Cereno Scientific's financial position?
Financial Health Score5/6
Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: CRNO B's short term assets (SEK64.8M) exceed its short term liabilities (SEK21.4M).
Long Term Liabilities: CRNO B's short term assets (SEK64.8M) exceed its long term liabilities (SEK400.0K).
Debt to Equity History and Analysis
Debt Level: CRNO B has more cash than its total debt.
Reducing Debt: CRNO B's debt to equity ratio has increased from 1.5% to 3.4% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CRNO B has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: CRNO B has sufficient cash runway for 1.5 years if free cash flow continues to reduce at historical rates of 26.4% each year.
Discover healthy companies
What is Cereno Scientific current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
|Cereno Scientific Dividend Yield vs Market|
|Company (Cereno Scientific)||n/a|
|Market Bottom 25% (SE)||1.8%|
|Market Top 25% (SE)||6.1%|
|Industry Average (Biotechs)||2.2%|
|Analyst forecast in 3 Years (Cereno Scientific)||n/a|
Notable Dividend: Unable to evaluate CRNO B's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CRNO B's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CRNO B's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CRNO B's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as CRNO B has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Sten Sorensen (63 yo)
Mr. Sten R. Sorensen serves as the Chief Executive Officer at Cereno Scientific AB (publ). Mr. Sorensen has extensive experience from the Pharmaceutical, Biotechnology and Finance sectors. His previous rol...
CEO Compensation Analysis
|Sten Sorensen's Compensation vs Cereno Scientific Earnings|
|Date||Total Comp.||Salary||Company Earnings|
|Jun 30 2022||n/a||n/a|
|Mar 31 2022||n/a||n/a|
|Dec 31 2021||n/a||n/a|
|Sep 30 2021||n/a||n/a|
|Jun 30 2021||n/a||n/a|
|Mar 31 2021||n/a||n/a|
|Dec 31 2020||n/a||n/a|
|Sep 30 2020||n/a||n/a|
|Jun 30 2020||n/a||n/a|
|Mar 31 2020||n/a||n/a|
|Dec 31 2019||n/a||n/a|
|Sep 30 2019||n/a||n/a|
|Jun 30 2019||n/a||n/a|
|Mar 31 2019||n/a||n/a|
|Dec 31 2018||n/a||n/a|
|Sep 30 2018||n/a||n/a|
|Jun 30 2018||n/a||n/a|
|Mar 31 2018||n/a||n/a|
|Dec 31 2017||n/a||n/a|
|Sep 30 2017||n/a||n/a|
|Jun 30 2017||n/a||n/a|
|Mar 31 2017||n/a||n/a|
|Dec 31 2016||n/a||n/a|
|Sep 30 2016||n/a||n/a|
|Jun 30 2016||n/a||n/a|
|Mar 31 2016||n/a||n/a|
|Dec 31 2015||kr153k||kr112k|
Compensation vs Market: Insufficient data to establish whether Sten's total compensation is reasonable compared to companies of similar size in the Swedish market.
Compensation vs Earnings: Insufficient data to compare Sten's compensation with company performance.
Experienced Management: CRNO B's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.
Experienced Board: CRNO B's board of directors are considered experienced (6.9 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
|Owner Type||Number of Shares||Ownership Percentage|
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 46.6%.
|Ownership||Name||Shares||Current Value||Change %||Portfolio %|
Cereno Scientific AB (publ)'s employee growth, exchange listings and data sources
- Name: Cereno Scientific AB (publ)
- Ticker: CRNO B
- Exchange: NGM
- Founded: 2012
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: kr299.996m
- Shares outstanding: 105.26m
- Website: https://www.cerenoscientific.com
Number of Employees
- Cereno Scientific AB (publ)
- Pepparedsleden 1
- Västra Götaland County
- 431 83
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|CRNO B||NGM (Nordic Growth Market)||Yes||Class B Shares||SE||SEK||Jun 2016|
|4A1||DB (Deutsche Boerse AG)||Yes||Class B Shares||DE||EUR||Jun 2016|
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/10/03 00:00|
|End of Day Share Price||2022/10/03 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.